Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) EBIT Margin (2016 - 2023)

Spyre Therapeutics' EBIT Margin history spans 7 years, with the latest figure at 23146.22% for Q2 2023.

  • For Q2 2023, EBIT Margin fell 1955854.0% year-over-year to 23146.22%; the TTM value through Mar 2024 reached 39428.92%, down 3263528.0%, while the annual FY2023 figure was 27347.97%, 2370774.0% down from the prior year.
  • EBIT Margin reached 23146.22% in Q2 2023 per SYRE's latest filing, down from 9497.98% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 55.88% in Q2 2021 to a low of 23146.22% in Q2 2023.
  • Average EBIT Margin over 3 years is 6777.45%, with a median of 3587.68% recorded in 2022.
  • Peak YoY movement for EBIT Margin: tumbled -353180bps in 2022, then tumbled -1955854bps in 2023.
  • A 3-year view of EBIT Margin shows it stood at 560.98% in 2021, then tumbled by -1933bps to 11405.95% in 2022, then plummeted by -103bps to 23146.22% in 2023.
  • Per Business Quant, the three most recent readings for SYRE's EBIT Margin are 23146.22% (Q2 2023), 9497.98% (Q1 2023), and 11405.95% (Q4 2022).